Published in Gynecol Oncol on November 05, 2007
Evaluation of TRANSKRIP ® Plus Chemotherapy in Recurrent-Persistent Cervical Cancer | NCT02446652
Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res (2008) 1.21
TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS One (2013) 1.00
Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. BMC Cancer (2009) 0.98
Emerging biological treatments for uterine cervical carcinoma. J Cancer (2014) 0.95
A novel radioresistant mechanism of galectin-1 mediated by H-Ras-dependent pathways in cervical cancer cells. Cell Death Dis (2012) 0.94
Treatment options in recurrent cervical cancer (Review). Oncol Lett (2010) 0.92
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group Study. Int J Gynecol Cancer (2009) 0.91
Beyond angiogenesis blockade: targeted therapy for advanced cervical cancer. J Gynecol Oncol (2014) 0.89
EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy. BMC Cancer (2008) 0.87
EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol (2014) 0.86
New molecular targets against cervical cancer. Int J Womens Health (2014) 0.85
Inhibition of the epidermal growth factor receptor by erlotinib prevents immortalization of human cervical cells by Human Papillomavirus type 16. Virology (2011) 0.82
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV. J Oncol (2010) 0.82
Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther (2014) 0.80
Targeting angiogenesis in gynecologic cancers. Hematol Oncol Clin North Am (2012) 0.79
Patient age, tumor appearance and tumor size are risk factors for early recurrence of cervical cancer. Mol Clin Oncol (2014) 0.78
Pharmacologic Management of Advanced Cervical Cancer: Antiangiogenesis Therapy and Immunotherapeutic Considerations. Drugs (2015) 0.78
Small intestine metastasis from cervical cancer with acute abdomen: A case report. Oncol Lett (2014) 0.77
Cytotoxic effect of lapatinib is restricted to human papillomavirus-positive head and neck squamous cell carcinoma cell lines. Onco Targets Ther (2015) 0.77
Therapeutic advances in women's cancers. Front Biosci (Schol Ed) (2011) 0.76
Chemotherapy and molecular targeting therapy for recurrent cervical cancer. Chin J Cancer Res (2016) 0.75
Prognostic Impact of Epidermal Growth Factor Receptor Overexpression in Patients with Cervical Cancer: A Meta-Analysis. PLoS One (2016) 0.75
A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer. Cancer Biol Ther (2015) 0.75
Nonsurgical management of cervical cancer: locally advanced, recurrent, and metastatic disease, survivorship, and beyond. Am Soc Clin Oncol Educ Book (2015) 0.75
Human cervical carcinomas and EGF-R tyrosine kinase inhibitors. Gynecol Oncol (2008) 0.75
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells. Toxicol Appl Pharmacol (2017) 0.75
Intensity-modulated radiotherapy combined with iodine-125 seed implantation in non-central recurrence of cervical cancer: A case report and literature review. Oncol Lett (2017) 0.75
International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol (2010) 2.94
A new technique for sampling duodenal contents: demonstration of upper small-bowel pathogens. Am J Trop Med Hyg (1970) 2.63
Gene expression profiling of primary breast carcinomas using arrays of candidate genes. Hum Mol Genet (2000) 2.15
A new function for platelets: IgE-dependent killing of schistosomes. Nature (1983) 2.11
[Results and fertility after conservative treatment of invasive epithelial ovarian cancer]. Gynecol Obstet Fertil (2002) 2.03
[Laparoscopic treatment of borderline ovarian tumor: analysis of 54 patients and clinical outcomes]. Gynecol Obstet Fertil (2005) 1.99
The immunological response of CBA mice to Trypanosoma musculi. I. Initial control of the infection and the effect of T-cell deprivation. Clin Exp Immunol (1974) 1.87
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer. Ann Oncol (2012) 1.82
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol (1999) 1.74
The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients. Eur J Cancer (2000) 1.74
Seroepidemiology of Strongyloides infection in the Southeast Asian refugee population in Canada. Am J Epidemiol (1990) 1.52
Randomized study of early hospital discharge following autologous blood SCT: medical outcomes and hospital costs. Bone Marrow Transplant (2011) 1.46
High-dose chemotherapy for ovarian carcinoma: long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol (2001) 1.45
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol (2004) 1.44
[Initial or interval debulking surgery for advanced stage ovarian cancer: state-of-the-art. How to select patients?]. Gynecol Obstet Fertil (2005) 1.44
Sequential taxane and anthracycline-containing neoadjuvant regimens: the sequential order impact. Breast (2010) 1.43
Intestinal parasite infection in the Kampuchean refugee population 6 years after resettlement in Canada. J Infect Dis (1992) 1.39
[Laparoscopic interiliacal lymphadenectomy in cancer of the uterine cervix: still the gold standard? A propos lymph node recurrences in 190 treated patients]. J Gynecol Obstet Biol Reprod (Paris) (2005) 1.38
Induction of cutaneous 'graft-versus-host like' reaction by recombinant IL-2 after autologous bone marrow transplantation. Bone Marrow Transplant (1995) 1.38
[Modalities and limits of conservative treatment of adenocarcinoma in situ of the uterine cervix: analysis of nine cases and review of the literature]. Gynecol Obstet Fertil (2003) 1.37
Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Ann Oncol (2003) 1.36
Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer (2000) 1.35
The persistance of Trypanosoma (Herpetosoma) musculi in the kidneys of immune CBA mice. Trans R Soc Trop Med Hyg (1972) 1.33
Etiology of urethral discharge in West Africa: the role of Mycoplasma genitalium and Trichomonas vaginalis. Bull World Health Organ (2001) 1.30
Epidemiology of Toxocariasis in the Montreal area. Prevalence of Toxocara and other helminth ova in dogs and soil. Can J Public Health (1977) 1.27
Desmoplastic small round cell tumors: results of a four-drug chemotherapy regimen in five adult patients. Cancer (1996) 1.23
The immunological response of CBA mice to Trypanosoma musculi: elimination of the parasite from the blood. Int J Parasitol (1975) 1.23
Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy. Oncogene (2006) 1.23
Discordance between physicians' estimations and breast cancer patients' self-assessment of side-effects of chemotherapy: an issue for quality of care. Br J Cancer (1997) 1.19
Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. Eur J Cancer (2004) 1.16
Correlated break at PARK2/FRA6E and loss of AF-6/Afadin protein expression are associated with poor outcome in breast cancer. Oncogene (2006) 1.15
Superiority of the ELISA technique over parasitological methods for detection of trichinellosis in slaughtered pigs in Canada. Can J Comp Med (1985) 1.13
Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol (2011) 1.13
Free human chorionic gonadotropin beta subunit in gonadal and nongonadal neoplasms. Cancer Res (1992) 1.13
Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Cancer (2001) 1.12
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumors. Ann Oncol (1997) 1.10
Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol (2003) 1.10
5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer (1989) 1.08
Advanced chondrosarcomas: role of chemotherapy and survival. Ann Oncol (2013) 1.08
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
The effect of reticulocytosis on Plasmodium vinckei infection in white mice. Action of phenylhydrazine and of repeated bleedings. Can J Microbiol (1971) 1.06
ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene (2007) 1.04
Contribution of surgery in patients with bulky residual disease after chemoradiation for advanced cervical carcinoma. Eur J Surg Oncol (2006) 1.03
Adult granulosa-cell tumor of the ovary: a retrospective study of 45 cases. Int J Gynecol Cancer (1997) 1.03
The immunological response of CBA mice to Trypanosoma musculi: mechanisms of protective immunity. Int J Parasitol (1975) 1.03
Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol. Am J Obstet Gynecol (1996) 1.02
Prognosis of stage III or IV primary peritoneal serous papillary carcinoma. Eur J Surg Oncol (2004) 1.01
Ablastin: control of Trypanosoma musculi infections in mice. Exp Parasitol (1975) 1.01
Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Ann Oncol (2011) 1.00
[Neuromuscular hamartoma]. Ann Pathol (1991) 1.00
The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet (2006) 1.00
Trypanosoma musculi infection in B-cell-deficient mice. Infect Immun (1984) 1.00
Local and distant failures after limited surgery with positive margins and radiotherapy for node-negative breast cancer. Int J Radiat Oncol Biol Phys (2000) 0.98
Unbiased quantitative assessment of Her-2 expression of circulating tumor cells in patients with metastatic and non-metastatic breast cancer. Ann Oncol (2012) 0.98
Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol (2003) 0.98
Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy. Int J Gynecol Cancer (2003) 0.98
Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia (2003) 0.97
DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer. Br J Cancer (2003) 0.96
Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol (2013) 0.96
A seven-gene prognostic model for platinum-treated ovarian carcinomas. Br J Cancer (2011) 0.96
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO. Br J Cancer (2013) 0.96
Detection of minimal levels of serum anti-Müllerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay. J Clin Endocrinol Metab (2000) 0.96
Aggressive surgical strategies in advanced ovarian cancer: a monocentric study of 203 stage IIIC and IV patients. Eur J Surg Oncol (2008) 0.96
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br J Cancer (1999) 0.96
Inflammatory breast cancer in Tunisia in the era of multimodality therapy. Ann Oncol (2007) 0.96
Autologous transplantation of blood stem cells mobilized with filgrastim alone in 93 patients with malignancies: the number of CD34+ cells reinfused is the only factor predicting both granulocyte and platelet recovery. J Hematother (1996) 0.96
Efficacy and safety of docetaxel (Taxotere) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience. Eur J Cancer (1999) 0.95
HIV infection among pregnant women in Bobo-Dioulasso, Burkina Faso: comparison of voluntary and blinded seroprevalence estimates. Int J STD AIDS (1999) 0.95
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial. Stem Cells (1994) 0.94
Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia (2005) 0.94
Comparison of anxiety, pain and discomfort in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow harvest. Bone Marrow Transplant (1995) 0.93
Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type. Ann Oncol (2007) 0.93
Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann Oncol (2008) 0.93
Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol (2002) 0.93
Prognostic value of initial surgical procedure for patients with uterine sarcoma: analysis of 123 patients. Eur J Gynaecol Oncol (2003) 0.92
Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution. Leuk Lymphoma (1998) 0.91
Results of conservative treatment in epithelial ovarian carcinoma. Cancer (2001) 0.91
Immunosuppression during Trypanosoma musculi infection in inbred strains of mice. J Clin Lab Immunol (1983) 0.91
Mucinous advanced epithelial ovarian carcinoma: clinical presentation and sensitivity to platinum-paclitaxel-based chemotherapy, the GINECO experience. Ann Oncol (2010) 0.91
Survival and reproductive function of 52 women treated with surgery and bleomycin, etoposide, cisplatin (BEP) chemotherapy for ovarian yolk sac tumor. Ann Oncol (2008) 0.90
Total laparoscopic radical hysterectomy for locally advanced cervical carcinoma (stages IIB, IIA and bulky stages IB) after concurrent chemoradiation therapy: surgical morbidity and oncological results. Gynecol Oncol (2009) 0.90
Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol (2000) 0.90
Local and distant recurrence after conservative management of "very low-risk" breast cancer are dependent events: a 10-year follow-up. Int J Radiat Oncol Biol Phys (1998) 0.90
Cost-effectiveness of repeated aphereses in poor mobilizers undergoing high-dose chemotherapy and autologous hematopoietic cell transplantation. Leukemia (2003) 0.89
Impact of adjuvant treatment modalities on the management of patients with stages I-II endometrial stromal sarcoma. Ann Oncol (2010) 0.89
Cell-mediated immunity during the infection of CBA mice with Trypanosoma musculi. Can J Microbiol (1974) 0.89
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs (2013) 0.89
Allogeneic hematopoietic stem cell transplantation in ovarian carcinoma: results of five patients. Bone Marrow Transplant (2002) 0.89
A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer (1996) 0.88
[Multisite validation study of questionnaire assessing out-patient satisfaction with care questionnaire in ambulatory chemotherapy or radiotherapy treatment]. Bull Cancer (2006) 0.88